Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRC01LS and VRC07-523LS in HIV-Infected Adults
NCT02840474Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Apr 2017
- Primary completion
- Jan 2020
- Modality
- Anti-infectious Disease mAbs
- Countries
- 2
01
Overview
Phase 1, open-label trial of VRC01LS and VRC07-523LS in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Participants Reporting Local Reactogenicity Signs and Symptoms at 3 days, Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms at 3 days and 3 more. Started Apr 2017; status: completed.
02
Drugs
VRC01LSVRC07-523LS
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02840474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02840474.